Epistem is discovering the key regulators of adult epithelial stem cells and developing protein therapeutics that control cell production in the areas of oncology, oncology supportive care (mucositis, alopecia) and epithelial disease.  

We have applied our discovery platform of expert knowledge of the behaviour of adult epithelial stem cells alongside high-resolution gene expression analysis to identify genes from which to identify soluble stem cell regulators. Production, purification, and testing of proteins is underway in our industry-standard in vivo functional stem cell assays.

Lead candidates that have demonstrated robust and reproducible in vivo activity are emerging from the recombinant proteins for further characterisation in our disease-specific models.

Epistem intends to advance its candidate therapeutics through the proof-of-concept stage in preclinical development and then to partner further development with drug companies.

Epistem will also enter into discovery partnerships with drug companies, initially in the area of oncology and cancer stem cells.